Nanotechnology-Based Drug Delivery Systems for Targeted Cancer Therapy
DOI:
Abstract
Nanotechnology has emerged as a transformative approach in cancer therapy by enabling precise, targeted, and controlled delivery of therapeutic agents. This systematic review aims to evaluate the clinical advances of nanotechnology-based drug delivery systems in oncology, focusing on their efficacy, safety, and translational potential. Using PRISMA guidelines, relevant studies from 2015 to 2025 were analyzed, including randomized clinical trials, cohort studies, and systematic reviews. Findings demonstrate that nanoparticle formulations—such as liposomes, polymeric nanoparticles, dendrimers, and gold nanoparticles—significantly enhance bioavailability and tumor-specific accumulation while minimizing off-target toxicity. For example, liposomal doxorubicin and albumin-bound paclitaxel have shown improved survival outcomes and reduced cardiotoxicity compared to conventional chemotherapy. Recent advances in stimuli-responsive and ligand-functionalized nanoparticles have further increased precision in drug release, resulting in better therapeutic indices in breast, lung, and prostate cancers. Despite these achievements, challenges remain in large-scale production, cost efficiency, and long-term biocompatibility. Regulatory hurdles and variability in patient-specific responses also limit broader adoption in clinical practice. Overall, nanotechnology-based drug delivery systems represent a paradigm shift in targeted cancer therapy, offering enhanced treatment precision, improved patient quality of life, and potential integration with immunotherapy and gene therapy approaches. Future clinical research should prioritize personalized nanomedicine, long-term safety monitoring, and scalable production to maximize clinical translation.
Downloads
Views : 410
Downloads : 214
References
H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin., vol. 71, no. 3, pp. 209–249, May 2021.
J. L. Zamorano, C. Gottfridsson, R. Asteggiano, D. Atar, L. Badimon, J. J. Bax et al., “The cancer patient and cardiology,” European Journal of Heart Failure, vol. 22, no. 12, pp. 2290–2309, 2020.
A. Narezkina, H. K. Narayan, and A. E. Zemljic-Harpf, “Molecular mechanisms of anthracycline cardiovascular toxicity,” Clinical Science, vol. 135, no. 10, pp. 1311–1332, 2021.
Y. Liu, Y. Zhang, H. Li, and T. Y. Hu, “Recent advances in the bench-to-bedside translation of cancer nanomedicines,” Acta Pharmaceutica Sinica B, vol. 15, no. 1, pp. 97–122, Jan. 2025.
Y. Huang, X. Guo, Y. Wu et al., “Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment,” Signal Transduction and Targeted Therapy, vol. 9, no. 34, 2024.
V. R. Shinde, N. Revi, S. Murugappan, S. P. Singh, and A. K. Rengan, “Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles,” Photodiagnosis and Photodynamic Therapy, vol. 39, p. 102915, Sep. 2022.
B. D. Cardoso, A. Souza, G. Nobrega, I. S. Afonso, L. B. Neves, C. Faria, J. Ribeiro, and R. A. Lima, “Progress in nanofluid technology: From conventional to green nanofluids for biomedical, heat transfer, and machining applications,” Nanomaterials, vol. 15, no. 16, p. 1242, 2025.
P. Shi, Z. Cheng, K. Zhao, et al., “Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics,” J. Nanobiotechnol., vol. 21, p. 103, 2023.
P. A. Cavallaro, M. De Santo, E. L. Belsito, C. Longobucco, M. Curcio, C. Morelli, L. Pasqua, and A. Leggio, “Peptides targeting HER2-positive breast cancer cells and applications in tumor imaging and delivery of chemotherapeutics,” Nanomaterials, vol. 13, no. 17, 2023.
Y. Wang, M. Lin, T. Fan, M. Zhou, R. Yin, and X. Wang, “Advances of stimuli-responsive amphiphilic copolymer micelles in tumor therapy,” Int. J. Nanomedicine, vol. 20, pp. 1–24, 2024.
K.-W. Ho, Y.-L. Liu, T.-Y. Liao, E.-S. Liu, and T.-L. Cheng, “Strategies for non-covalent attachment of antibodies to PEGylated nanoparticles for targeted drug delivery,” Int. J. Nanomedicine, vol. 19, 2024.
A. Crintea, A. G. Dutu, A. Sovrea, A.-M. Constantin, G. Samasca, A. L. Masalar, B. Ifju, E. Linga, L. Neamti, R. A. Tranca, Z. Fekete, C. N. Silaghi, and A. M. Craciun, "Nanocarriers for Drug Delivery: An Overview with Emphasis on Vitamin D and K Transportation," Nanomaterials, vol. 12, no. 8, p. 1376, Apr. 2022.
H. S. Han, S. Y. Koo, and K. Y. Choi, “Emerging nanoformulation strategies for phytocompounds and applications from drug delivery to phototherapy to imaging,” Bioactive Materials, vol. 14, pp. 182–205, Aug. 2022.
M. A. Raza, A. Firdous, U. Gupta, U. Patil, A. Singh, and A. Ajazuddin, “Emerging trends in designing the dendrimer-based drug delivery for antineoplastic therapies,” ACS Appl. Bio Mater., vol. 8, no. 7, pp. 5462–5495, Jun. 23, 2025.
M. Chehelgerdi, O. Q. B. Allela, R. D. C. Pecho, N. Jayasankar, D. P. Rao, T. Thamaraikani, M. Vasanthan, P. Viktor, N. Lakshmaiya, M. J. Saadh, A. Amajd, M. A. Abo-Zaid, R. Y. Castillo-Acobo, A. H. Ismail, A. H. Amin, and R. Akhavan-Sigari, “Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation,” Mol. Cancer, vol. 22, no. 1, p. 169, Oct. 9, 2023.
G. Murphy, D. J. Brayden, D. L. Cheung, A. Liew, M. Fitzgerald, and A. Pandit, “Albumin-based delivery systems: Recent advances, challenges, and opportunities,” J. Control. Release, vol. 380, pp. 375–395, Apr. 10, 2025.
H. Ghazal, A. Waqar, F. Yaseen, M. Shahid, M. Sultana, M. Tariq, M. K. Bashir, H. Tahseen, T. Raza, and F. Ahmad, “Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment,” Next Mater., vol. 2, Jan. 2024.
A. Havasi, S. S. Cainap, A. T. Havasi, and C. Cainap, “Ovarian cancer—Insights into platinum resistance and overcoming it,” Medicina (Kaunas), vol. 59, no. 3, p. 544, Mar. 10, 2023.
M. E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. G. Kieback, P. Tomczak, S. P. Ackland, F. Orlandi, L. Mellars, L. Alland, and C. Tendler; CAELYX Breast Cancer Study Group, “Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer,” Ann. Oncol., vol. 15, no. 3, pp. 440–449, Mar. 2004.
T. Safra, F. Muggia, S. Jeffers, D. D. Tsao-Wei, S. Groshen, O. Lyass, R. Henderson, G. Berry, and A. Gabizon, “Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m²,” Ann. Oncol., vol. 11, no. 8, pp. 1029–1033, Aug. 2000.
J. Viegas and B. Sarmento, “Bridging the gap between testing and clinics: exploring alternative pre-clinical models in melanoma research,” Adv. Drug Deliv. Rev., vol. 208, May 2024.
A. Naaz, H. R. Turnquist, V. S. Gorantla, and S. R. Little, “Drug delivery strategies for local immunomodulation in transplantation: Bridging the translational gap,” Adv. Drug Deliv. Rev., vol. 213, Oct. 2024.
D. Shi, D. Beasock, A. Fessler, J. Szebeni, J. Y. Ljubimova, K. A. Afonin, and M. A. Dobrovolskaia, “To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives,” Adv. Drug Deliv. Rev., vol. 180, Jan. 2022.
T. Lei, Y. Wang, Y. Zhang et al., “Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy,” Leukemia, vol. 38, pp. 2517–2543, 2024.
R. Bhattacharjee, A. Jana, A. Nandi, A. Sinha, A. Bhattacharjee, S. Mitra, S. Kar, A. Dey, S. K. Singh, R. S. Varma, P. K. Panda, M. Suar, and S. K. Verma, “Synergy of nanocarriers with CRISPR-Cas9 in an emerging technology platform for biomedical appliances: Current insights and perspectives,” Mater. Des., vol. 224, Dec. 2022.
T. Zhang, J. Ding, Q. Lv, M. Zhao, Y. Liu, Q. Wang, Y. Chen, H. Zhao, H. Ren, W. Jiang, L. Zhang, and B. Guo, “Strategies for organic nanoparticles delivering CRISPR/Cas9 for cancer therapy: Challenges and breakthroughs,” Mater. Des., vol. 244, Aug. 2024.
E. B. Souto, C. Blanco-Llamero, K. Krambeck, N. S. Kiran, C. Yashaswini, H. Postwala, P. Severino, R. Priefer, B. G. Prajapati, and R. Maheshwari, “Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives,” Acta Biomater., vol. 180, pp. 1–17, May 2024.
K. Cheng and R. Kalluri, “Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics,” Extracell. Vesicle, vol. 2, Dec. 2023.
P. K. Peitl, C. Rangger, P. Garnuszek, R. Mikolajczak, A. Hubalewska-Dydejczyk, T. Maina, P. Erba, and C. Decristoforo, “Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples,” J. Labelled Compd. Radiopharm., vol. 62, no. 10, pp. 673–683, 2019.
M. Sell, A. R. Lopes, M. Escudeiro, B. Esteves, A. R. Monteiro, T. Trindade, and L. Cruz-Lopes, “Application of nanoparticles in cancer treatment: A concise review,” Nanomaterials, vol. 13, no. 21, 2023.
H. Tian, T. Zhang, S. Qin et al., “Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies,” J. Hematol. Oncol., vol. 15, p. 132, 2022.
